Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate.

Goraya N, Simoni J, Jo CH, Wesson DE.

Clin J Am Soc Nephrol. 2013 Mar;8(3):371-81. doi: 10.2215/CJN.02430312. Epub 2013 Feb 7.

2.
3.

Does correction of metabolic acidosis slow chronic kidney disease progression?

Goraya N, Wesson DE.

Curr Opin Nephrol Hypertens. 2013 Mar;22(2):193-7. doi: 10.1097/MNH.0b013e32835dcbbe. Review.

PMID:
23380803
4.
5.

Effect of oral sodium bicarbonate supplementation on progression of chronic kidney disease in patients with chronic metabolic acidosis: study protocol for a randomized controlled trial (SoBic-Study).

Gaggl M, Cejka D, Plischke M, Heinze G, Fraunschiel M, Schmidt A, Hörl WH, Sunder-Plassmann G.

Trials. 2013 Jul 4;14:196. doi: 10.1186/1745-6215-14-196.

6.

Treatment of acidosis in CKD.

Yaqoob MM.

Clin J Am Soc Nephrol. 2013 Mar;8(3):342-3. doi: 10.2215/CJN.00240113. Epub 2013 Jan 31. No abstract available.

7.

Does oral sodium bicarbonate therapy improve function and quality of life in older patients with chronic kidney disease and low-grade acidosis (the BiCARB trial)? Study protocol for a randomized controlled trial.

Witham MD, Band MM, Littleford RC, Avenell A, Soiza RL, McMurdo ME, Sumukadas D, Ogston SA, Lamb EJ, Hampson G, McNamee P; BiCARB Study Group.

Trials. 2015 Aug 1;16:326. doi: 10.1186/s13063-015-0843-6.

8.

Effects of oral sodium bicarbonate in patients with CKD.

Abramowitz MK, Melamed ML, Bauer C, Raff AC, Hostetter TH.

Clin J Am Soc Nephrol. 2013 May;8(5):714-20. doi: 10.2215/CJN.08340812. Epub 2013 Feb 7.

9.

Very Low-Protein Diet (VLPD) Reduces Metabolic Acidosis in Subjects with Chronic Kidney Disease: The "Nutritional Light Signal" of the Renal Acid Load.

Di Iorio BR, Di Micco L, Marzocco S, De Simone E, De Blasio A, Sirico ML, Nardone L, On Behalf Of Ubi Study Group.

Nutrients. 2017 Jan 17;9(1). pii: E69. doi: 10.3390/nu9010069.

10.

[Electrolyte and acid-base balance disorders in advanced chronic kidney disease].

Alcázar Arroyo R.

Nefrologia. 2008;28 Suppl 3:87-93. Spanish.

11.

Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy.

Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE.

Kidney Int. 2010 Aug;78(3):303-9. doi: 10.1038/ki.2010.129. Epub 2010 May 5.

12.

Dietary management of chronic kidney disease: protein restriction and beyond.

Goraya N, Wesson DE.

Curr Opin Nephrol Hypertens. 2012 Nov;21(6):635-40. doi: 10.1097/MNH.0b013e328357a69b. Review.

PMID:
23079747
13.

Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.

Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, Ariyanayagam R, Al-Yassin A, Sharpe C, Vinen K.

Clin J Am Soc Nephrol. 2012 Aug;7(8):1234-41. doi: 10.2215/CJN.01150112. Epub 2012 May 17.

14.

Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy.

Weinberg JM, Appel LJ, Bakris G, Gassman JJ, Greene T, Kendrick CA, Wang X, Lash J, Lewis JA, Pogue V, Thornley-Brown D, Phillips RA; African American Study of Hypertension and Kidney Disease Collaborative Research Group.

Arch Intern Med. 2009 Sep 28;169(17):1587-94. doi: 10.1001/archinternmed.2009.284.

PMID:
19786678
15.

Estimated net endogenous acid production and serum bicarbonate in African Americans with chronic kidney disease.

Scialla JJ, Appel LJ, Astor BC, Miller ER 3rd, Beddhu S, Woodward M, Parekh RS, Anderson CA.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1526-32. doi: 10.2215/CJN.00150111. Epub 2011 Jun 23.

16.

Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.

Abe M, Suzuki H, Okada K, Maruyama N, Inoshita A, Baba S, Takashima H, Soma M.

Heart Vessels. 2013 Jul;28(4):442-52. doi: 10.1007/s00380-012-0260-7. Epub 2012 May 23.

PMID:
22618635
17.

Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.

Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell'Italia LJ, Cofield SS, Oparil S, Calhoun DA.

J Hum Hypertens. 2012 Aug;26(8):502-6. doi: 10.1038/jhh.2011.60. Epub 2011 Jun 16.

PMID:
21677673
18.

Low serum bicarbonate and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA).

Driver TH, Shlipak MG, Katz R, Goldenstein L, Sarnak MJ, Hoofnagle AN, Siscovick DS, Kestenbaum B, de Boer IH, Ix JH.

Am J Kidney Dis. 2014 Oct;64(4):534-41. doi: 10.1053/j.ajkd.2014.05.008. Epub 2014 Jun 18.

19.

Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR.

Phisitkul S, Khanna A, Simoni J, Broglio K, Sheather S, Rajab MH, Wesson DE.

Kidney Int. 2010 Apr;77(7):617-23. doi: 10.1038/ki.2009.519. Epub 2010 Jan 13.

20.

Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone.

Wesson DE, Simoni J, Broglio K, Sheather S.

Am J Physiol Renal Physiol. 2011 Apr;300(4):F830-7. doi: 10.1152/ajprenal.00587.2010. Epub 2011 Jan 26.

Supplemental Content

Support Center